Results 81 to 90 of about 45,546 (194)
Toxicity of Cytarabine Intravenous Constant Rate Infusion in Cats With Lymphoma
Veterinary and Comparative Oncology, EarlyView.ABSTRACT
Cytarabine intravenous constant rate infusion (IV CRI) toxicity in cats with lymphoma has not been well documented. We aimed to assess toxicities following cytarabine IV CRI as a single‐agent or within a multiagent protocol in cats with lymphoma. Medical records of cats with lymphoma treated with cytarabine IV CRI, with documented dose, route, Rachel Hanford, Katherine A. Skorupski, Robert B. Rebhun, Rachel V. Brady, Sami Al‐Nadaf, Amandine T. Lejeune +5 morewiley +1 more sourceImmune platelet transfusion refractoriness associated with anti‐CD36 alloimmunisation in a Brazilian patient with platelet CD36 deficiency
Vox Sanguinis, EarlyView.Abstract Background and Objectives
Immune platelet transfusion refractoriness (PTR) is usually mediated by anti‐HLA class I antibodies; immunisation against CD36 (platelet glycoprotein IV [GPIV]) is relatively rare. Platelet CD36 deficiency shows marked ethnic variability and is seldom reported in admixed Latin American populations.Rayane Dayse Alves Conserva, Luiz Frederico Bezerra Honorato Junior, Ana Paula Hitomi Yokoyama, Thiago Henrique Costa, Luis Henrique Cardoso Fedeli, Ana Cynira Franco Marret, Eduardo Perez Bastos, Fabio Pires de Souza Santos, Luana Nobrega Costa, Livia Chiosini de Nadai, Carolina Bonet‐Bub, Jose Mauro Kutner +11 morewiley +1 more sourceDiffuse purpuric eruption in a patient with acute myeloid leukemia
JAAD Case Reports, 2023 Zoha K. Momin, BS, Aya Alame, MD, Travis Vandergriff, MD, Cristina Thomas, MD, Kaveh Nezafati, MD +4 moredoaj +1 more sourceOlutasidenib Alone or in Combination With Azacitidine as a Bridge to Transplant in Relapsed/Refractory mIDH1 AML
European Journal of Haematology, EarlyView.Shira N. Dinner, Justin M. Watts, Jorge E. Cortes, Jay Yang, Maria R. Baer, Gail J. Roboz, Karen W. L. Yee, Antonio Curti, David C. Taussig, Jürgen Krauter, Thomas Prebet, Hua Tian, Aaron D. Sheppard, Pierre Peterlin, Carolyn Grove, Christian Récher, Stéphane de Botton +16 morewiley +1 more sourceAntiglioma effects of cytarabine on leptomeningeal metastasis of high-grade glioma by targeting the PI3K/Akt/mTOR pathway
Drug Design, Development and Therapy, 2017 Kai-Hong Zhao,1 Can Zhang,2 Yue Bai,1 Yan Li,1 Xun Kang,1 Jian-Xin Chen,1 Kun Yao,3 Tao Jiang,4 Xiao-Song Zhong,2 Wen-Bin Li1 1Department of Glioma, 2Clinical Center of Gene And Cell Engineering, Beijing Shijitan Hospital, 3Department of Neurosurgery ...Zhao KH, Zhang C, Bai Y, Li Y, Kang X, Chen JX, Yao K, Jiang T, Zhong XS, Li WB +9 moredoaj Real‐World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3‐Mutated AML: The PETHRATIFY Study
American Journal of Hematology, Volume 101, Issue 11, Page 2812-2826, November 2026.ABSTRACT
Mutations in FLT3 are present in approximately 30% of patients with AML. The addition of midostaurin (MIDO) to intensive chemotherapy (IC) became standard of care following the RATIFY trial, but comprehensive real‐world data spanning the full adult age spectrum and including both FLT3‐ITD and FLT3‐TKD mutations remain limited.Mónica Alejandra Romero Riquelme, Gaspar Aspas Requena, Pilar Lloret‐Madrid, Cristina Gil, Eliana Aguiar, Mar Tormo, Teresa del Bernal del Castillo, Eduardo Rodríguez Arbolí, Josefina Serrano, Joaquín Sánchez‐García, Carlos Rodríguez‐Medina, José Mário Mariz, Rosa Ayala, Joaquín Martínez‐López, María Luz Amigo, Susana Vives, Lorenzo Algarra Algarra, Raimundo García Boyero, Joana Brioso, Tamara Castaño, Juan M. Bergua Burgués, Olga Salamero, María Francisca Bass Maturana, Mercedes Colorado, María García Fortes, María José Sayas Lloris, Belén Vidriales Vicente, Carmen Chillón, Esther Pérez Santaolalla, María Dolores Madrigal, Jorge Labrador Gómez, María José García Pérez, Soledad Casado Calderón, Manuel Pérez Encinas, Amaia Balerdi Malcorra, María Solé Rodríguez, Lara María Gómez García, Pilar Herrera Puente, Olga Arce Fernández, Manuel Barrios García, Víctor Noriega, Rosa Fernández, Mamen Mateos, Carolina Lacalzada, Ágata Almela Gallego, María Carmen García Garay, Carmen Couto, José Antonio Pérez‐Simón, Eva Barragán González, Pau Montesinos +49 morewiley +1 more sourceEltrombopag during induction chemotherapy in older patients with newly diagnosed acute myeloid leukemia is safe and reduces platelet transfusion requirements: The EPAG‐2015 French Innovative Leukemia Organization phase 2 randomized trial
Cancer, Volume 132, Issue 21, 1 November 2026.Abstract Background
Elderly patients with acute myeloid leukemia (AML) treated with intensive chemotherapy are at risk of developing thrombopenia, which requires platelet transfusions. It would be interesting to provide them with thrombopoietin receptor agonists such as eltrombopag.Arnaud Pigneux, Pierre‐Yves Dumas, Marc Bernard, Norbert Vey, Audrey Bidet, Ariane Mineur, Aline Schmidt, Martin Carré, Mario Ojeda, Sarah Bertoli, Anne Banos, Pierre Peterlin, Romain Guièze, Yohan Desbrosses, Gabrielle Roth Guepin, Célestine Simand, Thibaut Leguay, Emmanuel Gyan, Eric Jourdan, Jean‐Philippe Vial, Tony Marchand, Yosr Hicheri, Marie C. Béné, Jean Francois Hamel, Christian Récher +24 morewiley +1 more sourceReal‐World Survival Outcomes of Venetoclax Combination Therapies in Acute Myeloid Leukemia: Impact of Minimal Residual Disease Status and Antifungal Prophylaxis
Hematological Oncology, Volume 44, Issue 6, November 2026.ABSTRACT
In recent years the addition of the oral BCL2 inhibitor venetoclax to hypomethylating agents (HMAs) has emerged as the standard‐of‐care for patients with acute myeloid leukemia (AML) who are not fit for intensive chemotherapy, significantly improving survival and quality‐of‐life.Mariarita Sciumè, Alessandro Bosi, Alfredo Marchetti, Fabio Serpenti, Pasquale De Roberto, Sonia Fabris, Francesco Versino, Elena Tagliaferri, Francesco Passamonti, Nicola Stefano Fracchiolla +9 morewiley +1 more source
